Claims for Patent: 5,807,838

Summary for Patent: 5,807,838

Title:	Oligonucleotide modulation of multidrug resistance-associated protein
Abstract:	Compositions and methods are provided for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of the synthesis or metabolism of multidrug resistance-associated protein (MRP) . In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding multidrug resistance-associated protein (MRP). Methods of treating animals suffering from diseases or conditions amenable to therapeutic intervention by modulating multidrug resistance with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to multidrug resistance-associated protein (MRP) are disclosed. Methods of preventing the development of multidrug resistance and of improving the efficacy of chemotherapy are also disclosed.
Inventor(s):	Baracchini, Jr.; Edgardo (San Diego, CA), Bennett; Clarence Frank (Carlsbad, CA)
Assignee:	Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	08/628,731
Patent Claims:	1. A method of decreasing the synthesis of multidrug resistance-associated protein in an animal suspected of having a condition which is characterized by changes in levels of multidrug resistance-associated protein comprising administering to an animal suspected of having a condition which is characterized by changes in levels of multidrug resistance-associated protein an effective amount of an oligonucleotide having 8 to 30 nucleotides complementary to a nucleic acid encoding multidrug resistance-associated protein and capable of decreasing the expression of multidrug resistance-associated protein so that synthesis of multidrug resistance-associated protein is decreased. 2. The method of claim 1 wherein said oligonucleotide is complementary to a transcription initiation site, translation initiation site, 5'-untranslated sequence, 3' untranslated sequence, coding sequence or an intron/exon junction of an mRNA encoding multidrug resistance-associated protein. 3. The method of claim 1 wherein said oligonucleotide is administered in a pharmaceutical composition comprising the oligonucleotide and a pharmaceutically acceptable carrier. 4. The method of claim 1 wherein the oligonucleotide is administered systemically. 5. The method of claim 1 wherein the oligonucleotide is administered in conjunction with a chemotherapeutic drug treatment for cancer. 6. The method of claim 1 wherein the oligonucleotide comprises SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16. 7. The method of claim 6 wherein the oligonucleotide comprises SEQ ID NO: 8 or SEQ ID NO: 9. 8. The method of claim 1 wherein at least one of the intersugar linkages between nucleotides of the oligonucleotide is a phosphorothioate linkage. 9. The method of claim 1 wherein the condition is a multidrug-resistant cancer. 10. The method of claim 9 wherein the multidrug-resistant cancer is small-cell lung cancer. 11. A method for improving the efficacy of a chemotherapeutic drug treatment of a disease, said method comprising administering in conjunction with a chemotherapeutic drug treatment an oligonucleotide comprising 8 to 30 nucleotides complementary to a nucleic acid encoding multidrug resistance-associated protein and capable of decreasing the expression of multidrug resistance-associated protein. 12. The method of claim 1 wherein the oligonucleotide comprises SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16. 13. The method of claim 12 wherein the oligonucleotide comprises SEQ ID NO: 8 or SEQ ID NO: 9. 14. The method of claim 11 wherein at least one of the intersugar linkages between nucleotides of the oligonucleotide is a phosphorothioate linkage. 15. The method of claim 11 wherein the disease is cancer. 16. The method of claim 15 wherein the disease is small-cell lung cancer. 17. A method for preventing the development of multidrug resistance during a chemotherapeutic drug treatment of a disease, said method comprising administering in conjunction with a chemotherapeutic drug treatment an oligonucleotide comprising 8 to 30 nucleotides complementary to a nucleic acid encoding multidrug resistance-associated protein and capable of decreasing the expression of multidrug resistance-associated protein so that synthesis of multidrug resistance-associated protein is decreased. 18. The method of claim 17 wherein the oligonucleotide comprises SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16. 19. The method of claim 18 wherein the oligonucleotide comprises SEQ ID NO: 8 or SEQ ID NO: 9. 20. The method of claim 17 wherein at least one of the intersugar linkages between nucleotides of the oligonucleotide is a phosphorothioate linkage. 21. The method of claim 17 wherein the disease is cancer. 22. The method of claim 21 wherein the disease is small-cell lung cancer. 23. The method of claim 1 wherein at least one of the nucleotides of the oligonucleotide is modified at the 2' position. 24. The method of claim 23 wherein the nucleotide modification is 2'-O-methyl, 2'-O-propyl or 2'-fluoro. 25. The method of claim 11 wherein at least one of the nucleotides of the oligonucleotide is modified at the 2' position. 26. The method of claim 25 wherein the nucleotide modification is 2'-O-methyl, 2'-O-propyl or 2'-fluoro. 27. The method of claim 17 wherein at least one of the nucleotides of the oligonucleotide is modified at the 2' position. 28. The method of claim 27 wherein the nucleotide modification is 2'-O-methyl, 2'-O-propyl or 2'-fluoro.

Details for Patent 5,807,838

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26